Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
heart failure
Biotech
Novo calls off $598M Heartseed collab, citing 'strategic reviews'
Japanese biotech Heartseed said it was "difficult to reasonably foresee" that Novo would scrap the 2021 deal, despite the pharma's restructuring.
Zoey Becker
Sep 30, 2025 1:55pm
Ajax, KKR launch heart failure startup with Boston Scientific
Mar 5, 2025 12:01pm
FIRE1 heats up with $120M for its heart failure monitor implant
Jan 7, 2025 2:40pm
Rivus posts data to back up muscle-sparing obesity drug claims
Sep 30, 2024 11:09am
Rivus’ phase 2 obesity-related heart failure trial hits endpoint
Aug 13, 2024 8:57am
Edwards inks $1.6B in deals for JenaValve, Endotronix
Jul 25, 2024 11:00am
